Abstract:Cell death resistance is a hallmark of tumor cells that drives tumorigenesis and drug resistance. Targeting cell death resistance-related genes to sensitize tumor cells and decrease their cell death threshold has attracted attention as a potential antitumor therapeutic strategy. However, the underlying mechanism is not fully understood. Recent studies have reported that NeuroD1, first discovered as a neurodifferentiation factor, is upregulated in various tumor cells and plays a crucial role in tumorigenesis. However, its involvement in tumor cell death resistance remains unknown. Here, we found that NeuroD1 was highly expressed in hepatocellular carcinoma (HCC) cells and was associated with tumor cell death resistance. We revealed that NeuroD1 enhanced HCC cell resistance to ferroptosis, a type of cell death caused by aberrant redox homeostasis that induces lipid peroxide accumulation, leading to increased HCC cell viability. NeuroD1 binds to the promoter of glutathione peroxidase 4 (GPX4), a key reductant that suppresses ferroptosis by reducing lipid peroxide, and activates its transcriptional activity, resulting in decreased lipid peroxide and ferroptosis. Subsequently, we showed that NeuroD1/GPX4-mediated ferroptosis resistance was crucial for HCC cell tumorigenic potential. These findings not only identify NeuroD1 as a regulator of tumor cell ferroptosis resistance but also reveal a novel molecular mechanism underlying the oncogenic function of NeuroD1. Furthermore, our findings suggest the potential of targeting NeuroD1 in antitumor therapy. Aberrant expression of cell death resistance-related genes is common in tumor cells and contributes to their resistance to cell death and tumorigenesis. Transcription factor NeuroD1 has been found to be highly expressed in various tumors and could promote tumorigenesis. However, whether it is involved in tumor cell death resistance remains unclear. In this study, we demonstrate that NeuroD1 enhances the resistance of hepatocellular carcinoma (HCC) cells to ferroptosis. Knocking down NeuroD1 leads to the increase of reactive oxygen species (ROS), toxic lipid peroxides, as well as DNA and mitochondrial damages. These subsequently trigger ferroptosis. We further revealed that NeuroD1 acts as a transcriptional activator of glutathione peroxidase 4 (GPX4), a key molecule that reduces lipid peroxide and thus protects cells against ferroptosis, thereby upregulates the expression level of GPX4 and suppresses HCC cells ferroptosis. Our results also confirmed the critical role of NeuroD1/GPX4 in tumorigenesis in vivo. Together, our findings reveal NeuroD1 as a crucial ferroptosis suppressor gene, thereby unraveling a novel mechanism of tumor cells ferroptosis resistance. Furthermore, our results suggest that targeting NeuroD1 might be a potential antitumor therapeutic strategy.

Peroxiredoxin 1 is Essential for Natamycin-Triggered Apoptosis and Protective Autophagy in Hepatocellular Carcinoma

Natural product pectolinarigenin inhibits proliferation, induces apoptosis, and causes G2/M phase arrest of HCC via PI3K/AKT/mTOR/ERK signaling pathway.

Peroxiredoxin 1 modulates oxidative stress resistance and cell apoptosis through stemness in liver cancer under non-thermal plasma treatment

A Novel TrxR1 Inhibitor Regulates NK and CD8+T Cell Infiltration and Cytotoxicity, Enhancing the Efficacy of Anti-PD-1 Immunotherapy Against Hepatocarcinoma

Metabolomic study of natrin-induced apoptosis in SMMC-7721 hepatocellular carcinoma cells by ultra-performance liquid chromatography-quadrupole/time-of-flight mass spectrometry

PNO1 inhibits autophagy-mediated ferroptosis by GSH metabolic reprogramming in hepatocellular carcinoma

Parvifoline AA Promotes Susceptibility of Hepatocarcinoma to Natural Killer Cell-Mediated Cytolysis by Targeting Peroxiredoxin.

Targeting NUPR1 with the Small Compound ZZW-115 is an Efficient Strategy to Treat Hepatocellular Carcinoma.

The PGC1α/NRF1-MPC1 axis suppresses tumor progression and enhances the sensitivity to sorafenib/doxorubicin treatment in hepatocellular carcinoma

NeuroD1-GPX4 signaling leads to ferroptosis resistance in hepatocellular carcinoma

The PGC1/NRF1-MPC1 Axis Suppresses Tumor Progression and Enhances the Sensitivity to Sorafenib/doxorubicin Treatment in Hepatocellular Carcinoma

Novel 2-Phenyloxypyrimidine Derivative Induces Apoptosis and Autophagy Via Inhibiting PI3K Pathway and Activating MAPK/ERK Signaling in Hepatocellular Carcinoma Cells.

NAD(P)H: Quinone Oxidoreductase 1 Overexpression in Hepatocellular Carcinoma Potentiates Apoptosis Evasion Through Regulating Stabilization of X-linked Inhibitor of Apoptosis Protein.

N-Acetyltransferase 10 Enhances Doxorubicin Resistance in Human Hepatocellular Carcinoma Cell Lines by Promoting the Epithelial-to-Mesenchymal Transition

Role of Thioredoxin Reductase 1 in Multidrug Resistance Caused by Reactive Oxygen Species-Related Cell Apoptosis in Hepatocellular Carcinoma

Synergistic inhibition of autophagy and neddylation pathways as a novel therapeutic approach for targeting liver cancer.

Chemotherapy-induced acetylation of ACLY by NAT10 promotes its nuclear accumulation and acetyl-CoA production to drive chemoresistance in hepatocellular carcinoma

Potent Inhibition of Gastric Cancer Cells by a Natural Compound Via Inhibiting TrxR1 Activity and Activating ROS-mediated P38 MAPK Pathway

Tumor Microenvironment Triggered Cascade‐Activation Nanoplatform for Synergistic and Precise Treatment of Hepatocellular Carcinoma

Uncovering the Mechanisms of Cryptotanshinone as a Therapeutic Agent Against Hepatocellular Carcinoma

PCK1 Downregulation Promotes TXNRD1 Expression and Hepatoma Cell Growth via the Nrf2/Keap1 Pathway